MetaCap

Mentari Therapeutics Inc. (MTRI)

NASDAQ: MTRIHealth CareBiotechnology: Pharmaceutical PreparationsUSD

14.70-0.545 (-3.57%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MTRI stock chart

Technical analysis

Key statistics

All statistics
Market cap
$856.94M
52-week range
5.75 – 23.30
Day range
13.01 – 14.78
Volume / Avg
85.12K / 19.42K
Beta
—
Next earnings
Feb 10, 2027

52-week range

$5.75$23.30

MTRI stock today

Shares of Mentari Therapeutics (MTRI) finished lower on Nov 20 at $14.70, a drop of 3.57% or $0.545 per share, versus the S&P 500's 3.70% decline. Volume was 4.4x the average at 85.12K shares, a sign of unusually heavy trading. At this level, MTRI sits in the middle of its 52-week range of $5.75 to $23.30: 36.9% below the high and 155.7% above the low.

Mentari Therapeutics's next earnings report is expected on Feb 10, 2027.

Summary generated from market data by MetaCap's automated system. Methodology

About Mentari Therapeutics

Company profile

Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways. The company was incorporated in 2025 and is based in Sacramento, California.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Gregory J. Divis Jr.
Headquarters
Sacramento, CA

Analyst forecast

Forecast

Consensus (1 analysts)

strong_buy

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Feb 10, 2027
Last reported (Sep/2026)
Nov 2, 2026
EPS actual vs est.
$-0.36 vs —

MTRI news

All MTRI news

Mentari Therapeutics peers

Health Care sector
MTRI peer companies
CompanyPrice% ChgMarket capCompare
LTGOLatigo Biotherapeutics Inc.13.00-1.81%$861.89Mvs MTRI
PHARPharming Group N.V. ADS11.54-5.10%$816.78Mvs MTRI
CRVSCorvus Pharmaceuticals Inc.9.67-3.40%$815.69Mvs MTRI
AKTSAktis Oncology Inc.16.15-1.52%$901.14Mvs MTRI
VSTMVerastem Inc.6.33-7.73%$797.67Mvs MTRI
SNDXSyndax Pharmaceuticals Inc.8.72-4.49%$785.05Mvs MTRI
IRWDIronwood Pharmaceuticals Inc. Class A4.70-0.21%$778.09Mvs MTRI
SVRASavara Inc.4.26-18.23%$939.86Mvs MTRI

Indexes, lists and sector

Mentari Therapeutics stock FAQ

What is Mentari Therapeutics's stock price today?

MTRI last traded at $14.70 as of Nov 20, 4:00 PM EST, down 3.57% on the day. Prices are delayed at least 15 minutes.

Does Mentari Therapeutics pay a dividend?

No. Mentari Therapeutics does not currently pay a regular cash dividend.

When is Mentari Therapeutics's next earnings date?

Mentari Therapeutics is expected to report earnings on Wednesday, February 10, 2027.

Who is Mentari Therapeutics's CEO?

Mr. Gregory J. Divis Jr. is the chief executive officer of Mentari Therapeutics Inc..

Has MTRI ever split its stock?

Yes. The most recent MTRI stock split was a 1-for-10 split on Nov 5, 2026.

What is the MTRI 52-week high?

The 52-week high for MTRI is $23.30 and the 52-week low is $5.75. The stock is currently 36.9% below its high.

Compare MTRI